Searching…
Aug 1, 1999 · DepoCyt (Cytarabine Liposomal) Injection Company: DepoTech Corporation Application No.: 21-041 Approval Date: 8/1/1999 Approval Letter (s) (PDF) Medical Review (s) (PDF) Chemistry Review...
Jul 13, 2017 · DepoCyt® (cytarabine liposome injection) (approved under NDA 021041) is indicated for the intrathecal treatment of lymphomatous meningitis, and has been manufactured at the Pacira facility in San Diego,...
Highlights of Prescribing Information These highlights do not include all the information needed to use DEPOCYT® safely and effectively. See full prescribing information for DEPOCYT. DEPOCYT (cytarabine liposome injec...
History of changes in FDA indication 1999-04-01: Initial accelerated approval for intrathecal treatment of lymphomatous meningitis. (Based on Glantz et al. 1999) 2007-04-19: Converted to regular approval for intrathec...
Depocyt. Home remedies and modern drug information. Rate: Efficacy, Side Effects, Danger. Read about medicines that really work to cure disease and help ailments.
"Skyepharma and Chiron Announce FDA Approval for Depocyt (TM)." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0592.018.
商品名:DEPOCYT,活性成分:CYTARABINE,申请号:021041,申请人:PACIRA PHARMS INC
DepoCyt® (cytarabine liposome injection) is indicated for the intrathecal treatment of lymphomatous meningitis. DepoCyt is a cytotoxic anticancer drug and, as with other potentially toxic...
Sep 13, 2025 · Depocyt received FDA approval in 1999 for lymphomatous meningitis, with subsequent studies aimed at expanding its therapeutic scope and optimizing dosing protocols.
DepoCyt is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat certain types of leukemia and lymphoma that have spread to the meninges – the layers of tissue that cover the brain.
